NYSE:BMYPharmaceuticals
Bristol Myers Squibb (BMY) Following FDA Acceptance Has An Undervalued Case
Bristol-Myers Squibb (BMY) is back in focus after the FDA accepted its New Drug Application for mezigdomide, an oral CELMoD in combination therapy for relapsed or refractory multiple myeloma.
See our latest analysis for Bristol-Myers Squibb.
The FDA filing sits against a backdrop of improving sentiment in Bristol-Myers Squibb, with the stock at US$59.34 after a 1-year total shareholder return of 31.37% and an 11.00% year to date share price return, suggesting momentum has been building...